Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The malignant clone and the bone-marrow environment.

Klaus Podar1, Paul G Richardson, Teru Hideshima

  • 1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu

Best Practice & Research. Clinical Haematology
|December 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Oncogene·2024
Same author

Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

Oncogene·2024
Same author

Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

Oncogene·2024
Same author

Editorial Expression of Concern: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.

Oncogene·2024
Same author

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.

Blood cancer journal·2024
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Multiple myeloma (MM) involves abnormal plasma cells in bone marrow. New therapies target MM cells and their microenvironment, but relapse necessitates further research for better outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow.
  • The bone marrow microenvironment is crucial for MM progression and drug resistance.
  • Existing therapies like thalidomide, bortezomib, and lenalidomide show efficacy but do not prevent relapse.

Purpose of the Study:

  • To review the current understanding of the MM cell clone and its interaction with the bone marrow microenvironment.
  • To explore how the microenvironment influences MM cell growth, survival, migration, and drug resistance.
  • To identify potential therapeutic strategies based on the MM cell-BM microenvironment relationship.

Main Methods:

  • Literature review of existing research on multiple myeloma.

Related Experiment Videos

  • Analysis of the molecular mechanisms underlying the MM cell clone and bone marrow microenvironment interactions.
  • Evaluation of current and emerging therapeutic strategies targeting MM.

    • Main Results:

    • Novel therapies targeting MM cells and their microenvironment inhibit MM cell growth, survival, and migration.
    • These agents also block growth factor secretion and angiogenesis, and can enhance anti-MM immunity.
    • Despite therapeutic advances, MM inevitably relapses, highlighting the need for improved treatments.

    Conclusions:

    • Understanding the reciprocal relationship between MM cells and the bone marrow microenvironment is key to developing new therapies.
    • Targeting extracellular matrix proteins and accessory cells within the BM may offer novel treatment avenues.
    • Restoring bone marrow homeostasis is essential for improving outcomes in multiple myeloma patients.